相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes
Caroline A. Nelson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management
Anastasiya Muntyanu et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2021)
Immune checkpoint inhibitor-induced vitiligo in advanced melanoma could be related to increased levels of CCL19
T. Fujimura et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma
Ambra Di Altobrando et al.
DERMATOLOGIC THERAPY (2020)
Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency
Seiichi Yano et al.
EUROPEAN JOURNAL OF CANCER (2020)
Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib
Ryo Amagai et al.
JOURNAL OF DERMATOLOGY (2020)
Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
Brendan Curti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
Y. Nakamura et al.
ANNALS OF ONCOLOGY (2020)
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
Tomoko Kobayashi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers
Taku Fujimura et al.
BIOMOLECULES (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma
Taku Fujimura et al.
MELANOMA RESEARCH (2020)
Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
Yumi Kambayashi et al.
CASE REPORTS IN ONCOLOGY (2020)
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma
Yasuhiro Fujisawa et al.
CANCER MEDICINE (2019)
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma
Sophia Kreft et al.
EUROPEAN JOURNAL OF CANCER (2019)
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Elisa A. Rozeman et al.
LANCET ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen J. Gogas et al.
EUROPEAN JOURNAL OF CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A. Ascierto et al.
JAMA ONCOLOGY (2019)
Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
Austin Greco et al.
CANCERS (2019)
Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection
Taku Fujimura et al.
FRONTIERS IN MEDICINE (2019)
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
Taku Fujimura et al.
FRONTIERS IN MEDICINE (2019)
Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
Yumi Kambayashi et al.
FRONTIERS IN MEDICINE (2019)
Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages
Taku Fujimura et al.
EXPERIMENTAL DERMATOLOGY (2018)
Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab
Taku Fujimura et al.
JOURNAL OF DERMATOLOGY (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population
Y. Fujisawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Liqin Wang et al.
CELL (2018)
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Michael B. Atkins et al.
CLINICAL CANCER RESEARCH (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients
Yasuhiro Fujisawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2018)
Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance
Yoshio Kiyohara et al.
JOURNAL OF DERMATOLOGY (2018)
HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy
Taku Fujimura et al.
JOURNAL OF DERMATOLOGY (2018)
Diabetes and Blood Glucose Disorders Under Anti-PD1
Quentin Magis et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report
Yusuke Muto et al.
MELANOMA RESEARCH (2018)
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
Taku Fujimura et al.
Oncotarget (2018)
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
Elizabeth Ahern et al.
ONCOIMMUNOLOGY (2018)
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
Meghan J. Mooradian et al.
ONCOIMMUNOLOGY (2018)
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S. Carlino et al.
EUROPEAN JOURNAL OF CANCER (2018)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy
Elizabeth Ahern et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma
Sebastien Corre et al.
NATURE COMMUNICATIONS (2018)
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
Taku Fujimura et al.
FRONTIERS IN ONCOLOGY (2018)
Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient
Taku Fujimura et al.
JOURNAL OF DERMATOLOGY (2017)
Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
Kenjiro Namikawa et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma
Taku Fujimura et al.
ONCOTARGET (2017)
Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma
Renier Heijkants et al.
Oncotarget (2017)
Elevated circulating levels of the interferon-γ- induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still's disease
Jae Ho Han et al.
SCIENTIFIC REPORTS (2017)
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P. B. Chapman et al.
ANNALS OF ONCOLOGY (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
Naoya Yamazaki et al.
CANCER SCIENCE (2017)
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
Naoya Yamazaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review
Stephanie G. C. Kroeze et al.
CANCER TREATMENT REVIEWS (2017)
The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma
Alexander N. Shoushtari et al.
CANCER (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma
Sadanori Furudate et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2016)
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
Michele Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages
Aya Kakizaki et al.
ONCOIMMUNOLOGY (2015)
Comparison of CD163+CD206+M2 Macrophages in the Lesional Skin of Bullous Pemphigoid and Pemphigus Vulgaris: The Possible Pathogenesis of Bullous Pemphigoid
Sadanori Furudate et al.
DERMATOLOGY (2014)
sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia
S. Colafrancesco et al.
IMMUNOLOGIC RESEARCH (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Comparison of Interleukin-17-Producing Cells in Different Clinical Types of Alopecia Areata
Genichi Tojo et al.
DERMATOLOGY (2013)
Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly
T. Matsumoto et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
Antonio Daponte et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma
Richard W. Joseph et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial
F. Egberts et al.
ANNALS OF ONCOLOGY (2011)
A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma
Valerie P. Grignol et al.
JOURNAL OF IMMUNOTHERAPY (2011)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Subpopulation of CD163-Positive Macrophages Is Classically Activated in Psoriasis
Judilyn Fuentes-Duculan et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Perilesional treatment of metastatic melanoma with interferon-β
T. Fujimura et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2009)
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: A randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group
R Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma:: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
A Hauschild et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
